{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:41:41Z","timestamp":1788316901352,"version":"build-2803163510"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated long survival for the treatment of advanced non-small cell lung cancer (NSCLC). However, the effect and safety of ICI rechallenge have not been fully evaluated. The aim of this study was to investigate the efficacy and safety of ICI rechallenge in NSCLC patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We defined \u2018rechallenge\u2019 as re-administration of ICIs for patients who were previously treated with ICIs and discontinued treatment for any reason, and received subsequent chemotherapy. We retrospectively analyzed the histories of 434 patients with advanced NSCLC who received ICIs from December 2015 to December 2017 at seven centers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 317 patients discontinued the ICI treatment, and 14 patients (4.4%) received ICI rechallenge. All 14 patients discontinued the first ICI due to disease progression. Eight patients received the same kind of ICIs, and six patients received different ICIs. Median progression-free survival and overall survival were 1.5 months [95% confidence interval (CI): 0.8\u20132.6] and 6.5 months [95% CI: 1.4\u201319.0], respectively. The objective response rate was 7.1%, and the disease control rate was 21.4%. Two of three patients who achieved at least a stable disease, received radiotherapy between the first and second ICIs. Adverse events were not significantly different compared with the first ICIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this study, the effect of ICI rechallenge was limited. Careful consideration of the administration of ICI rechallenge is necessary. This report involved a small number of cases, so further large prospective studies are warranted to confirm the efficacy of ICI rechallenge and to investigate predictive markers to identify a patient population in which ICI rechallenge is effective.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyz066","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T15:19:17Z","timestamp":1555427957000},"page":"762-765","source":"Crossref","is-referenced-by-count":65,"title":["The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer"],"prefix":"10.1093","volume":"49","author":[{"given":"Hiromi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2545-3052","authenticated-orcid":false,"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[{"name":"Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Kudo","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Iwakuni Medical Center, Iwakuni, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Minami","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Okayama Medical Center, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Murakami","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[{"name":"General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ninomiya","sequence":"additional","affiliation":[{"name":"Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan"},{"name":"Health Service Center, Okayama University, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijiro","family":"Harada","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Shikoku Cancer Center, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yasugi","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Okayama Medical Center, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[{"name":"Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan"},{"name":"Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tabata","sequence":"additional","affiliation":[{"name":"Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[{"name":"Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"2019090612551460900_hyz066C1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"2019090612551460900_hyz066C2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"2019090612551460900_hyz066C3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2019090612551460900_hyz066C4","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2019090612551460900_hyz066C5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"2019090612551460900_hyz066C6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2019090612551460900_hyz066C7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.lungcan.2011.03.010","article-title":"Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection","volume":"74","author":"Hata","year":"2011","journal-title":"Lung Cancer"},{"key":"2019090612551460900_hyz066C8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00280-018-3585-9","article-title":"Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases","volume":"81","author":"Fujita","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019090612551460900_hyz066C9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00280-017-3444-0","article-title":"Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab","volume":"80","author":"Nomura","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019090612551460900_hyz066C10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"2019090612551460900_hyz066C11","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1158\/1078-0432.CCR-14-2959","article-title":"Immune checkpoint modulation for non\u2013small cell lung cancer","volume":"21","author":"Soria","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2019090612551460900_hyz066C12","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/j.cllc.2017.09.002","article-title":"Analysis of early death in Japanese patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"19","author":"Inoue","year":"2018","journal-title":"Clin Lung Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyz066\/28648635\/hyz066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/8\/762\/29738616\/hyz066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T12:55:32Z","timestamp":1567774532000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/49\/8\/762\/5489526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,5,15]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz066","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,5,15]]}}}